• PRINT/CD-ROM: Despatched within 2 to 4 working days.

Competitive Outlook on Apoptosis in Oncology

  • Publication Date:December 2006
  • Publisher:Bioseeker
  • Product Type: Report
  • Pages:152

Competitive Outlook on Apoptosis in Oncology

Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis of cancer cells.

Scope of this report

  • In-depth competitive landscape assessment of the apoptopic market in oncology
  • Thorough review of utilized targets in apoptopic drug development
  • Thorough review of approved drugs
  • Progress analysis of five major cancer indications, including players, drugs, clinical progress and pitfalls
  • Research and analysis highlights

There are today over 190 apoptopic drugs in active development for the treatment of more than 40 different cancer indications. The top five pursued cancer indications are: breast cancer, leukemia, lung cancer, lymphoma and prostate cancer. A thorough target analysis of drugs in development reveals more than 130 candidate targets for triggering apoptosis in cancer cells.

Competitive forces are reviewed, showing market leaders, active players and changes in the competitive landscape. There are only one big pharma company represented among the top 10 players in apoptopic drug development in oncology. The acquisition of Idun Pharmaceutical in 2005 by Pfizer is a principal example of a further step in big pharma strategy to augment their internal research and development efforts with high-potential, externally sourced product candidates and technologies.

Key reasons to read this report

  • Understand the clinical and strategic challenges to the commercialization of apoptopic cancer drugs
  • Assess opportunities and risks for the continued development of apoptopic agents in five major cancer indications.
  • Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development

Some of the almost 80 drugs included in this analysis

2-methoxyestradiol, AEE-788, aglycon protopanaxadiol, aplidine, ARQ-501, arsenic trioxide, BMS-387032, canertinib dihydrochloride, canfosfamide hydrochloride, combretastatin A-4 prodrug, idronoxil, indisulam, INGN-201, mapatumumab, motexafin gadolinium, oblimersen sodium, OGX-011, patupilone, PXD-101, rubitecan, tipifarnib, trabectedin etc.

Some of the more than 100 companies included in this analysis

Alfacell Corporation, AnorMED, Antigenics, Antisoma, ArQule, Array BioPharma, Attenuon, Bionovo, Bristol-Myers Squibb, Cephalon, ChemGenex Pharmaceuticals, Cougar Biotechnology, Cyclacel Group, Eisai, Eli Lilly, EntreMed, Erimos, Gardant, Gemin X Biotechnologies, Genta, Geron, GPC Biotech, Human Genome Sciences, Introgen Therapeutics, Johnson & Johnson, Lorus Therapeutics, Madaus, MethylGene, Novartis, Novogen, OncoGenex Technologies, OXiGENE, PanaGin, Pfizer, Pharmacyclics, PharmaMar, Seattle Genetics, SuperGen, Taxolog, Telik, TopoTarget, ViroTarg, ZymoGenetics etc.

  • 1 Executive Summary
  • 2 Cancer Highlights
  • 3 Methodology
  • 4 Table of Contents
    • 4.1 List of Boxes
    • 4.2 List of Figures
    • 4.3 List of Tables
  • 5 Introduction to Apoptosis in Oncology
  • 6 Apoptosis Competitive Landscape in Oncology
    • 6.1 Countries & Players: Who are In the Lead?
      • 6.1.1 Top 10 Players Dominate The Developmental Pipeline
    • 6.2 Deals & Alliances in Apoptosis Drug Development
      • 6.2.1 Review of Deals and Alliances Initiated in 2006
      • 6.2.2 Review of Deals and Alliances Initiated in 2005
      • 6.2.3 Review of Deals and Alliances Initiated in 2004
      • 6.2.4 Review of Deals and Alliances Initiated in 2003
      • 6.2.5 Review of Deals and Alliances Initiated in 2002
      • 6.2.6 Review of Deals and Alliances Initiated in 2001
  • 7 Approved Apoptopic Cancer Drugs: Performance
  • 8 Target Analysis in Apoptosis
    • 8.1 Targets of Late Stage Apoptopic Drugs in Development
      • 8.1.1 B-cell CLL/lymphoma 2
      • 8.1.2 Caspase 3
      • 8.1.3 CD4 molecule
      • 8.1.4 Cytosolic ovarian carcinoma antigen 1
      • 8.1.5 Eukaryotic translation elongation factor 2
      • 8.1.6 Farnesyltransferase, CAAX box, alpha
      • 8.1.7 Fc fragment of IgE
      • 8.1.8 Histone deacetylase 1
      • 8.1.9 Histone deacetylase 2
      • 8.1.10 Interleukin 13 receptor, alpha 1
      • 8.1.11 Phosphodiesterase 2A, cGMP-stimulated
      • 8.1.12 Phosphodiesterase 5A, cGMP-specific
      • 8.1.13 Protein kinase C, beta 1
      • 8.1.14 Steroid 5-alpha-reductase, alpha polypeptide 1
      • 8.1.15 Topoisomerase (DNA) I
      • 8.1.16 Topoisomerase (DNA) II alpha
      • 8.1.17 Tubulin, beta polypeptide
      • 8.1.18 p53 protein
    • 8.2 Apoptopic Drugs and Their Targets According to Top 5 Cancer Indications
      • 8.2.1 Targets in Breast Cancer
      • 8.2.2 Targets in Leukemia
      • 8.2.3 Targets in Lung Cancer
      • 8.2.4 Targets in Lymphoma
      • 8.2.5 Targets in Prostate Cancer
  • 9 Apoptopic Drugs in Development: By Major Indications
    • 9.1 General Drug Developmental Overview
      • 9.1.1 Apoptopic Drugs in Phase III Clinical Development
      • 9.1.2 Failed Apoptopic Drugs in Oncology
    • 9.2 Progress Analysis - Breast Cancer
      • 9.2.1 Phase I Clinical Development
      • 9.2.2 Phase II Clinical Development
      • 9.2.3 Phase III Clinical Development
    • 9.3 Progress Analysis - Leukemia
      • 9.3.1 Phase I Clinical Development
      • 9.3.2 Phase II Clinical Development
      • 9.3.3 Phase III Clinical Development
    • 9.4 Progress Analysis - Lung Cancer
      • 9.4.1 Phase I Clinical Development
      • 9.4.2 Phase II Clinical Development
      • 9.4.3 Phase III Clinical Development
    • 9.5 Progress Analysis - Lymphoma
      • 9.5.1 Phase I Clinical Development
      • 9.5.2 Phase II Clinical Development
      • 9.5.3 Phase III Clinical Development
    • 9.6 Progress Analysis - Prostate Cancer
      • 9.6.1 Phase I Clinical Development
      • 9.6.2 Phase II Clinical Development
      • 9.6.3 Phase III Clinical Development
  • 10 Disclaimer
    • 10.1 Liability
    • 10.2 Completeness
  • 11 Appendix I: Complete List of Apoptopic Drugs in Development in Oncology
  • 12 Drug Index
  • 13 Company Index
  • List of Boxes
    • Box 1: Business & Market - PXD-101
    • Box 2: Business & Market - MG-98
    • Box 3: Business & Market - VX-680
    • Box 4: Business & Market - Ceflatonin
    • Box 5: Business & Market - Oblimersen sodium
    • Box 6: Business & Market - motexafin gadolinium
    • Box 7: Business & Market - 1D09C3
    • Box 8: Business & Market - PCK-3145
    • Box 9: Business & Market - ME-2
  • List of Figures
    • Figure 1: Top 5 Countries in Apoptopic Cancer Research
    • Figure 2: Top 10 Companies' Clinical Trial Progress in Apoptopic Drug Development
    • Figure 3: Trial Distribution of the Entire Apoptopic Pipeline in Oncology
    • Figure 4: Distribution of ApoptopicTrials in Breast Cancer
    • Figure 5: Distribution of Apoptopic Drug Trials in Leukemia
    • Figure 6: Distribution of Apoptopic Drug Trials in Lung Cancer
    • Figure 7: Distribution of Apoptopic Drug Trials in Lymphoma
    • Figure 8: Distribution of Apoptopic Drug Trials in Prostate Cancer
  • List of Tables
    • Table 1: Top 10's Apoptopic Pipeline Drugs
    • Table 2: Deals & Alliances in Apoptosis Drug Development in Oncology
    • Table 3: Companies with Apoptopic Cancer Drugs on the Market
    • Table 4: List of 120 Known Targets in Apoptosis Drug Development
    • Table 5: Known Targets of Late Stage Apoptopic Drugs Development
    • Table 6: Drugs with Bcl-2 as a Target
    • Table 7: Drugs with Casp-3 as a Target
    • Table 8: Drugs with CD4 molecule as a Target
    • Table 9: Drugs with Cova-1 as a Target
    • Table 10: Drugs with Eef-2 as a Target
    • Table 11: Drugs with Fnta as a Target
    • Table 12: Drugs with Fcer-2 as a Target
    • Table 13: Drugs with Hdac-1 as a Target
    • Table 14: Drugs with Hdac-2 as a Target
    • Table 15: Drugs with IL13-RA1 as a Target
    • Table 16: Drugs with Pde-2A as a Target
    • Table 17: Drugs with Pde-5A as a Target
    • Table 18: Drugs with Prkcb-1 as a Target
    • Table 19: Drugs with Srd-5A1 as a Target
    • Table 20: Drugs with Top-1 as a Target
    • Table 21: Drugs with Top-2A as a Target
    • Table 22: Drugs with Top-2A as a Target
    • Table 23: Drugs with p53 protein as a Target
    • Table 24: Breast Cancer Targets in Apoptopic Drug Development
    • Table 25: Leukemia Targets in Apoptopic Drug Development
    • Table 26: Lung Cancer Targets in Apoptopic Drug Development
    • Table 27: Lymhoma Targets in Apoptopic Drug Development
    • Table 28: Prostate Cancer Targets in Apoptopic Drug Development
    • Table 29: Top 10 Cancer Indications in Apoptopic Cancer Drugs
    • Table 30: Overview of Apoptopic Drugs in Phase III Clinical Development
    • Table 31: Recently Ceased or Discountinued Phase I to Phase III Apoptopic Drugs
    • Table 32: List of Phase I to Phase III Apoptopic Drugs in Development for Breast Cancer
    • Table 33: List of Phase I to Phase III Apoptopic Drugs in Development for Leukemia
    • Table 34: List of Phase I to Phase III Apoptopic Drugs in Development for Lung Cancer
    • Table 35: List of Phase I to Phase III Apoptopic Drugs in Development for Lymphoma
    • Table 36: List of Phase I to Phase III Apoptopic Drugs in Development for Prostate Cancer
+44 20 8816 8548

Ask a question about Competitive Outlook on Apoptosis in Oncology

Enter the characters you see in the picture below
Captcha